clinical trial · NCT06394518
Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)Prosthetic Joints Infection (PJI)TNP-2092 for injectionplacebo
brief summary
This is a phase 1, single-center, randomized, double-blind, placebo-controlled, dose-escalation clinical trial of single and multiple intravenous doses of TNP-2092 for injection in healthy Chinese participants.
started
Jul 7, 2022
primary completion
Feb 24, 2023
completion
Feb 24, 2023
last updated
May 1, 2024
official title
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol